INGN vs. ALTU, COCH, RBOT, CLGN, MLSS, SMTI, ZJYL, NKTR, RLMD, and KPTI
Should you be buying Inogen stock or one of its competitors? The main competitors of Inogen include Altitude Acquisition (ALTU), Envoy Medical (COCH), Vicarious Surgical (RBOT), CollPlant Biotechnologies (CLGN), Milestone Scientific (MLSS), Sanara MedTech (SMTI), Jin Medical International (ZJYL), Nektar Therapeutics (NKTR), Relmada Therapeutics (RLMD), and Karyopharm Therapeutics (KPTI). These companies are all part of the "medical" sector.
Altitude Acquisition (NASDAQ:ALTU) and Inogen (NASDAQ:INGN) are both small-cap financial services companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Inogen has a consensus price target of $13.67, suggesting a potential upside of 69.35%. Given Altitude Acquisition's higher probable upside, analysts clearly believe Inogen is more favorable than Altitude Acquisition.
Altitude Acquisition has higher earnings, but lower revenue than Inogen.
Altitude Acquisition has a net margin of 0.00% compared to Altitude Acquisition's net margin of -32.46%. Inogen's return on equity of 0.00% beat Altitude Acquisition's return on equity.
7.0% of Altitude Acquisition shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 85.0% of Altitude Acquisition shares are held by insiders. Comparatively, 0.6% of Inogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Inogen had 2 more articles in the media than Altitude Acquisition. MarketBeat recorded 2 mentions for Inogen and 0 mentions for Altitude Acquisition. Altitude Acquisition's average media sentiment score of 0.97 beat Inogen's score of 0.00 indicating that Inogen is being referred to more favorably in the news media.
Inogen received 386 more outperform votes than Altitude Acquisition when rated by MarketBeat users.
Altitude Acquisition has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
Summary
Inogen beats Altitude Acquisition on 8 of the 13 factors compared between the two stocks.
Get Inogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools